1[1]Lane NE.An update on glucocorticoid-induced osteoporosis.Rheum Dis Clin North Am,2001,271(1):235-253.
2[2]Patschan D,Loddenkemper K,Buttgereit F.Molecular mechanisms of glucocorticoid-induced osteoporosis.Bone,2001,29(6):498-505.
3[3]Wong CA,Walsh LJ,Smith CJ,et al.Inhaled corticosteriod use and bone-mineral density in patients with asthma.Lancet,2000,355(9222):1399-1403.
4[4]Cave A,Arlett P,Lee E.Inhaled and nasal corticosteroids:factors affecting the risks of systemic adverse effects.Pharmacol Ther,1999,83(3):153-179.
5[5]Clowes JA,Peel N,Eastell R.Glucocorticoid-induced osteoporosis.Curr Opin in Rheumatol,2001,13(4):326-332.
6[6]van Staa TP,Leufkens HG,Cooper C.Use of inhaled corticosteroids and risk of fractures.J Bone Miner Res,2001,16(3):581-588.
7[7]Wierzbicki AS,Reynolds TM.Statins and fractures.Lancet 2001,357(9271):1887-1889.
8[8]American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis:recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis:2001 update.Arthritis Rheum,2001,44(7):1496-1503.
9[9]Wallach S,Cohen S,Reid DM,et al.Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.Calcif Tissue Int,2000,67(4): 277-285.
10[10]Adachi JD,Saag KG,Delmas PD,et al.Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids:a randomized,double-blind,placebo-controlled extension trial.Arthritis Rheum,2001,44(1):202-211.
9YOSIPOVITCH G, HOON T S ,L EOK G C. Suggested rationale for preventian and treatment of glucocorticoid induced bone loss in dermatologie patients[J ]. Arch Dermatol,2001 , 137 (4) :477-481.
